Compare Summit Therapeutics Inc (SMMT) vs Zillow Group Inc Class C (Z) Price & Performance

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.

Zillow Group (Z) trades at $29.17, up 6.93% in the past 24 hours, showing strong momentum despite mixed technical signals. The company has demonstrated improving fundamentals with revenue growing from $2.2B in 2024 to $2.6B in 2025, and net income turning positive at $23M after a $112M loss the prior year. Recent earnings show two consecutive beats, with Q2 2026 EPS of $0.52 exceeding expectations of $0.4459. Analyst consensus remains divided with a $60.33 price target representing significant upside potential from current levels.

The outlook for Zillow appears cautiously optimistic with improving profitability and strategic AI integration, though the stock faces headwinds from high mortgage rates and housing market volatility. The company's transition to an integrated transaction platform shows promise, but execution risks remain amid competitive pressures and regulatory scrutiny. With a P/E ratio of 126.83 indicating premium valuation, investors should monitor housing market trends and the company's ability to sustain recent earnings momentum.